{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T04:39:11Z","timestamp":1785213551085,"version":"3.55.0"},"reference-count":36,"publisher":"Oxford University Press (OUP)","issue":"1","license":[{"start":{"date-parts":[[2006,1,1]],"date-time":"2006-01-01T00:00:00Z","timestamp":1136073600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2006,1,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>A 2-year prospective, partially randomized open-label trial comparing oral alendronate with intravenous pamidronate therapy in children with OI showed equivalence in increasing total body BMD, spine BMD, and linear growth, and decreasing bone turnover and fracture incidence. Children with mild OI had greater responses than severe OI in BMD and growth.<\/jats:p>\n               <jats:p>Introduction: Bisphosphonate therapies increase BMD and may reduce fractures in children with osteogenesis imperfecta (OI). A study directly comparing oral with intravenous bisphosphonate has not been published. This clinical trial compares oral alendronate with intravenous pamidronate in children with OI using an open-label, prospective, 2-year, randomized design.<\/jats:p>\n               <jats:p>Materials and Methods: Children over the age of 3 years were stratified by bone age, pubertal stage, and type of OI and then randomized to receive oral alendronate 1 mg\/kg\/day in tablet form or intravenous pamidronate, 3 mg\/kg\/4 months. One child was assigned to pamidronate. One child randomized to intravenous pamidronate changed to oral alendronate. Eighteen children completed 12 months of therapy: nine on oral alendronate and nine on intravenous pamidronate. Primary outcome efficacy was increase in BMD. Secondary outcomes included changes in bone turnover biomarkers, fracture incidence, and growth.<\/jats:p>\n               <jats:p>Results: Total body and lumbar spine BMD increased, turnover markers decreased, and linear growth increased equivalently with oral and intravenous therapy. Fracture incidence showed a trend to decrease in both groups, with a significant decrease in fracture rates when the oral and intravenous groups were pooled. There were greater responses in BMD and growth in children with milder OI (type I) than those with more severe disease (types III and IV), but there were no significant effects of age or pubertal stage.<\/jats:p>\n               <jats:p>Conclusions: Oral and intravenous bisphosphonate therapies are equally effective in children with OI and are particularly effective in milder forms. The oral route is highly acceptable in children and has practical advantages over the intravenous route.<\/jats:p>","DOI":"10.1359\/jbmr.051006","type":"journal-article","created":{"date-parts":[[2006,4,26]],"date-time":"2006-04-26T13:27:09Z","timestamp":1146058029000},"page":"132-140","source":"Crossref","is-referenced-by-count":101,"title":["Two-Year Clinical Trial of Oral Alendronate Versus Intravenous Pamidronate in Children With Osteogenesis Imperfecta"],"prefix":"10.1093","volume":"21","author":[{"given":"Linda A","family":"DiMeglio","sequence":"first","affiliation":[{"name":"Department of Pediatrics, Section of Pediatric Endocrinology and Diabetology, Indiana University School of Medicine, Indianapolis, Indiana, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Munro","family":"Peacock","sequence":"additional","affiliation":[{"name":"Department of Medicine, Indiana University School of Medicine, Indianapolis, Indiana, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2009,12,4]]},"reference":[{"key":"2024013019400094500_bib1","first-page":"195","article-title":"Osteogenesis imperfecta and other heritable disorders of bone","volume":"11","author":"Paterson","year":"1997","journal-title":"J Clin Endocrinol Metab"},{"key":"2024013019400094500_bib2","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1136\/jmg.16.2.101","article-title":"Genetic heterogeneity in osteogenesis imperfecta","volume":"16","author":"Sillence","year":"1979","journal-title":"J Med Genet"},{"key":"2024013019400094500_bib3","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.1016\/S0140-6736(04)16051-0","article-title":"Osteogenesis imperfecta","volume":"363","author":"Rauch","year":"2004","journal-title":"Lancet"},{"key":"2024013019400094500_bib4","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1056\/NEJMoa030897","article-title":"Ten years' experience with alendronate for osteoporosis in postmenopausal women","volume":"350","author":"Bone","year":"2004","journal-title":"N Engl J Med"},{"key":"2024013019400094500_bib5","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1056\/NEJM199803123381107","article-title":"Treatment of postmenopausal osteoporosis","volume":"338","author":"Eastell","year":"1998","journal-title":"N Engl J Med"},{"key":"2024013019400094500_bib6","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1056\/NEJM199810013391402","article-title":"Cyclic administration of pamidronate in children with severe osteogenesis imperfecta","volume":"339","author":"Glorieux","year":"1998","journal-title":"N Engl J Med"},{"key":"2024013019400094500_bib7","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1542\/peds.111.3.573","article-title":"Intravenous bisphosphonate therapy in children with osteogenesis imperfecta","volume":"111","author":"Falk","year":"2003","journal-title":"Pediatrics"},{"key":"2024013019400094500_bib8","first-page":"1846","article-title":"Pamidronate treatment of severe osteogenesis imperfecta in children under 3 years of age","volume":"85","author":"Plotkin","year":"2000","journal-title":"J Clin Endocrinol Metab"},{"key":"2024013019400094500_bib9","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1111\/j.1651-2227.1998.tb01388.x","article-title":"Beneficial effect of bisphosphonate during five years of treatment of severe osteogenesis imperfecta","volume":"87","author":"Astrom","year":"1998","journal-title":"Acta Paediatr"},{"key":"2024013019400094500_bib10","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1016\/S0022-3476(97)70074-X","article-title":"Intravenous pamidronate treatment in osteogenesis imperfecta","volume":"131","author":"Bembi","year":"1997","journal-title":"J Pediatr"},{"key":"2024013019400094500_bib11","first-page":"S12","article-title":"Alendronate in the Treatment of Pediatric Osteogenesis Imperfecta","volume":"19","author":"Glorieux","year":"2004","journal-title":"J Bone Miner Res"},{"key":"2024013019400094500_bib12","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1007\/s004310050715","article-title":"Treatment of osteogenesis imperfecta with the bisphosphonate olpadronate (dimethylaminohydroxypropylidene bisphosphonate)","volume":"156","author":"Landsmeer-Beker","year":"1997","journal-title":"Eur J Pediatr"},{"key":"2024013019400094500_bib13","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.1016\/S0140-6736(04)16101-1","article-title":"Skeletal effects and functional outcome with olpadronate in children with osteogenesis imperfecta: A 2-year randomised placebo-controlled study","volume":"363","author":"Sakkers","year":"2004","journal-title":"Lancet"},{"key":"2024013019400094500_bib14","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1016\/j.bone.2004.07.003","article-title":"Intravenous pamidronate treatment of children under 36 months of age with osteogenesis imperfecta","volume":"35","author":"DiMeglio","year":"2004","journal-title":"Bone"},{"key":"2024013019400094500_bib15","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1515\/JPEM.2005.18.1.43","article-title":"A comparison of oral and intravenous bisphosphonate therapy for children with osteogenesis imperfecta","volume":"18","author":"DiMeglio","year":"2005","journal-title":"J Pediatr Endocrinol Metab"},{"key":"2024013019400094500_bib16","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1016\/S0022-3476(85)80501-1","article-title":"Clinical longitudinal standards for height and height velocity for North American children","volume":"107","author":"Tanner","year":"1985","journal-title":"J Pediatr"},{"key":"2024013019400094500_bib17","author":"Nigrin","year":"2000"},{"key":"2024013019400094500_bib18","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1136\/adc.45.239.13","article-title":"Variations in the pattern of pubertal changes in boys","volume":"45","author":"Marshall","year":"1970","journal-title":"Arch Dis Child"},{"key":"2024013019400094500_bib19","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1136\/adc.44.235.291","article-title":"Variation in pattern of pubertal changes in girls","volume":"44","author":"Marshall","year":"1969","journal-title":"Arch Dis Child"},{"key":"2024013019400094500_bib20","first-page":"S401","article-title":"The pharmacokinetics and short-term safety of alendronate in children and adolescents with osteogenesis imperfect (OI) type I","volume":"17S1","author":"Ward","year":"2002","journal-title":"J Bone Miner Res"},{"key":"2024013019400094500_bib21","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/8756-3282(95)00445-9","article-title":"Bisphosphonates: A review of their pharmacokinetic properties","volume":"18","author":"Lin","year":"1996","journal-title":"Bone"},{"key":"2024013019400094500_bib22","volume-title":"Bisphosphonates in Bone Disease","author":"Fleisch","year":"2000"},{"key":"2024013019400094500_bib23","volume-title":"Bone Density in Children","author":"Anonymous","year":"1993"},{"key":"2024013019400094500_bib24","volume-title":"Radiographic Atlas of Skeletal Development of the Hand & Wrist","author":"Greulich","year":"1959","edition":"2nd ed"},{"key":"2024013019400094500_bib25","doi-asserted-by":"crossref","first-page":"1779","DOI":"10.1359\/JBMR.040814","article-title":"Delayed osteotomy but not fracture healing in pediatric osteogenesis imperfecta patients receiving pamidronate","volume":"19","author":"Munns","year":"2004","journal-title":"J Bone Miner Res"},{"key":"2024013019400094500_bib26","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1007\/s00198-002-1334-7","article-title":"Assessing the reproducibility of quantitative ultrasound parameters with standardized coefficient of variation or intraclass correlation coefficient: A unique approach","volume":"14","author":"Giraudeau","year":"2003","journal-title":"Osteoporos Int"},{"key":"2024013019400094500_bib27","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1210\/edrv.19.1.0325","article-title":"Bisphosphonates: Mechanism of action","volume":"19","author":"Fleisch","year":"1998","journal-title":"Endocr Rev"},{"key":"2024013019400094500_bib28","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1136\/adc.86.5.356","article-title":"Beneficial effect of long term intravenous bisphosphonate treatment of osteogenesis imperfecta","volume":"86","author":"Astrom","year":"2002","journal-title":"Arch Dis Child"},{"key":"2024013019400094500_bib29","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1007\/s004310100844","article-title":"Cyclic pamidronate infusion improves bone mineralisation and reduces fracture incidence in osteogenesis imperfecta","volume":"160","author":"Lee","year":"2001","journal-title":"Eur J Pediatr"},{"key":"2024013019400094500_bib30","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1210\/jc.2002-021371","article-title":"Osteogenesis imperfecta types I, III, and IV: Effect of pamidronate therapy on bone and mineral metabolism","volume":"88","author":"Rauch","year":"2003","journal-title":"J Clin Endocrinol Metab"},{"key":"2024013019400094500_bib31","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1172\/JCI0215952","article-title":"The effects of intravenous pamidronate on the bone tissue of children and adolescents with osteogenesis imperfecta","volume":"110","author":"Rauch","year":"2002","journal-title":"J Clin Invest"},{"key":"2024013019400094500_bib32","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1007\/BF02556213","article-title":"Changes in apatite crystal size in bones of patients with osteogenesis imperfecta","volume":"49","author":"Vetter","year":"1991","journal-title":"Calcif Tissue Int"},{"key":"2024013019400094500_bib33","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1016\/S8756-3282(00)00376-8","article-title":"Alendronate increases bone strength by increasing the mean degree of mineralization of bone tissue in osteoporotic women","volume":"27","author":"Boivin","year":"2000","journal-title":"Bone"},{"key":"2024013019400094500_bib34","first-page":"S384","article-title":"Height and weight development during long-term therapy with cyclical intravenous pamidronate in children and adolescents with osteogenesis imperfecta types I, III and IV","volume":"17","author":"Zeitlin","year":"2002","journal-title":"J Bone Miner Res"},{"key":"2024013019400094500_bib35","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1056\/NEJMoa023110","article-title":"Bisphosphonate-induced osteopetrosis","volume":"349","author":"Whyte","year":"2003","journal-title":"N Engl J Med"},{"key":"2024013019400094500_bib36","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1016\/S0278-2391(03)00720-1","article-title":"Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: A growing epidemic","volume":"61","author":"Marx","year":"2003","journal-title":"J Oral Maxillofac Surg"}],"container-title":["Journal of Bone and Mineral Research"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1359%2FJBMR.051006","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/jbmr\/article-pdf\/21\/1\/132\/56480372\/5650210115.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jbmr\/article-pdf\/21\/1\/132\/56480372\/5650210115.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,13]],"date-time":"2024-03-13T14:45:36Z","timestamp":1710341136000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jbmr\/article\/21\/1\/132-140\/7593383"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,1,1]]},"references-count":36,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2009,12,4]]},"published-print":{"date-parts":[[2006,1,1]]}},"URL":"https:\/\/doi.org\/10.1359\/jbmr.051006","relation":{},"ISSN":["0884-0431","1523-4681"],"issn-type":[{"value":"0884-0431","type":"print"},{"value":"1523-4681","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2006,1,1]]},"published":{"date-parts":[[2006,1,1]]}}}